Metabotropic Receptors For Glutamate Type 3 In Parkinson's

NCT03998787 | Unknown

• 1 other identifier: ALBE_01
• Study Type: observational
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

Parkinson's disease (PD) is characterized by bradykinesia, rigidity, and tremor. Several scientific pieces of evidence, based on the use of kinematic techniques, have allowed quantifying objectively the alterations of the voluntary movement in the different stages of the disease. In recent years, several studies using transcranial magnetic stimulation (TMS) techniques, have also shown abnormalities in neurophysiological parameters of the primary motor cortex (M1) in patients with MP, in particular, a reduction in cortical excitability and synaptic plasticity of M1. In addition to the central role played by a dopaminergic deficit in MP, recent evidence suggests a possible involvement of the neurotransmitter glutamatergic system. In the present monocentric observational study, the investigators propose to assess possible correlations between polymorphisms of metabotropic glutamate type 3 receptors (mGlu3), clinical evaluation scales, alterations of kinematic motion parameters and neurophysiological parameters of M1.

Conditions

Neuroscience; Movement Disorders

Keywords

Parkinson's disease; Neurophysiology

Outcome Measures

Primary Outcomes (2)

• Neurophysiological assessment of PD patients

  Kinematic analysis of movement (i.e. amplitude and velocity)

  1 hours

• Neurophysiological assessment of PD patients

  Transcranial magnetic stimulation of primary motor cortex (i.e. aamplitude of motor evoked potentials)

  1 hour

Secondary Outcomes (1)

• Genetic analysis

  5 minutes

Study Arms (2)

Patients with Parkinson's disease

Patients with Parkinson's disease

Other: Neurophysiological assessment

Healthy Subjects

Healthy subjects

Other: Neurophysiological assessment

Interventions

Neurophysiological assessment OTHER

Kinematic analysis of movement and transcranial magnetic stimulation

Healthy Subjects; Patients with Parkinson's disease

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study involves the recruitment of 20 patients with Parkinson's disease, diagnosed according to current clinical criteria and 20 healthy control subjects. Patients with motor fluctuations and dyskinesia will be excluded. Recruitment of patients and control subjects will be carried out at the IRCCS NEUROMED Institute, Pozzilli (IS). All patients will undergo blood sampling to assess polymorphisms of metabotropic glutamate type 3 (mGlu3) receptors. All study participants will give informed consent to the experimental procedures, which will be approved by the local ethics committee and conducted in accordance with the Helsinki Declaration.

You may qualify if:

• Clinical diagnosis of Parkinson's disease
• Must be able to participate to the experimental session

You may not qualify if:

• Controindications to transcranial magnetic stimulation.
• Presence of dyskinesias

Sponsors & Collaborators

• Neuromed IRCCS: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples

MeSH Terms

Conditions

Movement Disorders; Parkinson Disease

Condition Hierarchy (Ancestors)

Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Alfredo Berardelli

  IRCCS Neuromed

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Alfredo Berardelli

CONTACT

+390649914700; alfredo.berardelli@uniroma1.it

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: OTHER
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Pincipal Investigator

Study Record Dates

• First Submitted: June 14, 2019
• First Posted: June 26, 2019
• Study Start: March 1, 2020
• Primary Completion: October 1, 2020
• Study Completion: September 1, 2022
• Last Updated: February 26, 2020

Record last verified: 2020-02